Morphine for the Treatment of Pain in Patients With Breast Cancer
| Status: | Completed |
|---|---|
| Conditions: | Chronic Pain |
| Therapuetic Areas: | Musculoskeletal |
| Healthy: | No |
| Age Range: | Any - 120 |
| Updated: | 4/21/2016 |
| Start Date: | May 1992 |
| End Date: | June 2001 |
Peripheral Effects of Opioid Analgesia in Patients Undergoing Axillary Node Dissection
RATIONALE: Morphine helps to relieve the pain associated with cancer surgery. Giving
morphine in different ways may offer more pain relief.
PURPOSE: This randomized clinical trial is studying how well morphine injected directly into
the underarm area works compared with morphine injected into the back of the shoulder in
treating pain in patients who have breast cancer and who are undergoing axillary lymph node
dissection.
morphine in different ways may offer more pain relief.
PURPOSE: This randomized clinical trial is studying how well morphine injected directly into
the underarm area works compared with morphine injected into the back of the shoulder in
treating pain in patients who have breast cancer and who are undergoing axillary lymph node
dissection.
OBJECTIVES: I. Determine whether morphine injected at the site of surgery can control pain
from surgery.
OUTLINE: This is a prospective, double blind, randomized study. Patients are randomized into
3 groups with 6 patients in each group. Group 1 receives morphine diluted in normal saline
(NS), which is administered in the axillary region at the completion of surgery before
surgical closure. The area is flooded and the solution is allowed to remain in the wound for
5 minutes. Group 2 (control group) receives NS only, administered in the same fashion as
group 1. Group 3 receives morphine subcutaneously in the deltoid area, ipsilateral to the
site of surgery, at the beginning of wound closure. Postoperatively, patients
self-administer IV fentanyl analgesia through a patient controlled analgesia pump.
Comparisons of daily IV fentanyl utilization is done among the three groups. Quality of pain
is assessed via visual analog pain scores four times a day at 2, 4, 6, and 24 hours
postoperatively.
PROJECTED ACCRUAL: A total of 18 patients will be accrued over a period of 2 years.
from surgery.
OUTLINE: This is a prospective, double blind, randomized study. Patients are randomized into
3 groups with 6 patients in each group. Group 1 receives morphine diluted in normal saline
(NS), which is administered in the axillary region at the completion of surgery before
surgical closure. The area is flooded and the solution is allowed to remain in the wound for
5 minutes. Group 2 (control group) receives NS only, administered in the same fashion as
group 1. Group 3 receives morphine subcutaneously in the deltoid area, ipsilateral to the
site of surgery, at the beginning of wound closure. Postoperatively, patients
self-administer IV fentanyl analgesia through a patient controlled analgesia pump.
Comparisons of daily IV fentanyl utilization is done among the three groups. Quality of pain
is assessed via visual analog pain scores four times a day at 2, 4, 6, and 24 hours
postoperatively.
PROJECTED ACCRUAL: A total of 18 patients will be accrued over a period of 2 years.
DISEASE CHARACTERISTICS: Patients with breast cancer who are scheduled to undergo axillary
node dissection
PATIENT CHARACTERISTICS: See General Eligibility Criteria
PRIOR CONCURRENT THERAPY: No oral-equivalent doses of morphine greater than 10 mg a day --
Patient Characteristics-- Age: Not specified Sex: Not specified Other: Not allergic to
morphine
We found this trial at
1
site
Roswell Park Cancer Institute Welcome to Roswell Park Cancer Institute (RPCI), America's first cancer center...
Click here to add this to my saved trials
